国内亨丁顿舞蹈症治疗方法的研究进展
Research Progress on Treatment Methods for Huntington’s Disease in China
DOI: 10.12677/jcpm.2024.34347, PDF,   
作者: 郝文丽:华北理工大学基础医学院,河北 唐山;林 佳*:华北理工大学生命科学学院,河北 唐山
关键词: 亨丁顿舞蹈症神经退行性疾病中枢神经原位再生技术二甲双胍GPR52受体Huntington’s Disease Neurodegenerative Disease Central Nervous System Regeneration in Situ Metformin GPR52 Receptor
摘要: 亨丁顿舞蹈症是一种以常染色体显性遗传为特征的神经退行性疾病,其临床表现主要表现为运动障碍、认知功能障碍以及精神障碍。早期科学家们对亨丁顿舞蹈症的致病机制进行了深入研究,目前,国内针对该病的治疗方法主要分为两大类。一类是技术治疗,涵盖了神经细胞异种移植技术、超声技术联合微泡技术和中枢神经原位再生技术等。另一类是药物治疗,包括表没食子儿茶素没食子酸酯、Deutetrabenazin药物、二甲双胍和GPR52受体反向激动剂等。尽管这些治疗方法目前仍处于早期实验阶段,尚未广泛应用于临床治疗,但它们为亨丁顿舞蹈症患者的康复带来了希望。本文旨在综述近年来国内在亨丁顿舞蹈症治疗方法研究方面取得的进展。
Abstract: Huntington’s disease is a neurodegenerative disease characterized by autosomal dominant inheritance. Its clinical manifestations are mainly manifested as movement disorders, cognitive dysfunction and mental disorders. Early scientists conducted in-depth research on the pathogenic mechanism of Huntington’s disease. At present, domestic treatment methods for the disease are mainly divided into two categories. The first category is technical treatment, which covers nerve cell xenograft technology, ultrasound technology combined with microbubble technology, and central nerve in situ regeneration technology. The other category is drug therapy, including epigallocatechin gallate, Deutetrabenazin drugs, metformin and GPR52 receptor inverse agonists. Although these treatments are still in the early experimental stages and have not yet been widely used in clinical treatment, they offer hope for the recovery of Huntington’s chorea patients. This article aims to review the progress made in the research on treatment methods for Huntington’s disease in recent years.
文章引用:郝文丽, 林佳. 国内亨丁顿舞蹈症治疗方法的研究进展[J]. 临床个性化医学, 2024, 3(4): 2429-2436. https://doi.org/10.12677/jcpm.2024.34347

参考文献

[1] 周维军, 郭妍, 任立霞, 等. 亨廷顿舞蹈症治疗药物研究进展[J]. 中国临床药学杂志, 2023, 32(6): 476-480.
[2] 安平, 鲁伯埙. 亨廷顿舞蹈症研究现状[J]. 中国细胞生物学学报, 2018, 40(10): 1621-1632.
[3] 毕瑞明, 付加芳. 亨丁顿舞蹈症家系的调查[J]. 中国优生与遗传杂志, 2007, 15(8): 118+60.
[4] Harris, G.J., Aylward, E.H., Peyser, C.E., Pearlson, G.D., Brandt, J., Roberts-Twillie, J.V., et al. (1996) Single Photon Emission Computed Tomographic Blood Flow and Magnetic Resonance Volume Imaging of Basal Ganglia in Huntington’s Disease. Archives of Neurology, 53, 316-324. [Google Scholar] [CrossRef] [PubMed]
[5] 刘畅, 吕晓菁, 郑秀玉, 等. 亨廷顿舞蹈症发病机制的研究进展[J]. 生物技术通讯, 2008, 19(4): 619-622.
[6] Jiang, A., Handley, R.R., Lehnert, K. and Snell, R.G. (2023) From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research. International Journal of Molecular Sciences, 24, Article 13021. [Google Scholar] [CrossRef] [PubMed]
[7] 李永丰, 李宁娆, 吴宇蔚. 多巴胺神经元在抑郁症动物模型中的适应性改变研究现状与展望[J]. 解剖学研究, 2024, 46(3): 272-277.
[8] 胡桂花, 吴雪红, 叶秀兰. 中枢神经递质DA、5-HT、NE水平与首发抑郁障碍患者疗效的关系[J]. 医学理论与实践, 2024, 37(12): 2097-2099.
[9] Roos, R.A. (2010) Huntington’s Disease: A Clinical Review. Orphanet Journal of Rare Diseases, 5, Article No. 40. [Google Scholar] [CrossRef] [PubMed]
[10] 周娟平, 苏刚, 陈丽霞, 等. 线粒体相关内质网膜在神经退行性疾病中的研究进展[J]. 中国细胞生物学学报, 2020, 42(8): 1465-1471.
[11] 秦思月, 高举, 王兴龙, 等. 神经退行性疾病中线粒体动态变化研究进展[J]. 中国科学·生命科学, 2018, 48(11): 1197-1208.
[12] 邱奥望, 刘展, 郭军, 等. 神经炎症与神经退行性疾病的关系[J]. 生理科学进展, 2011, 42(5): 353-358.
[13] 单凯悦, 董瑞, 张高峰, 等. 小胶质细胞及其外泌体在中枢神经退行性疾病中的研究进展[J]. 中华老年医学杂志, 2023, 42(2): 219-224.
[14] Kassubek, J., Henkel, K., Kramer, B., et al. (2004) Topography of Cerebral Atrophy in Early Huntington’s Disease: A Voxel Based Morphometric MRL Study. Journal of Neurology, Neurosurgery and Psychiatry, 75, 213-220.
[15] Hobbs, N.Z., Barnes, J., Frost, C., Henley, S.M.D., Wild, E.J., Macdonald, K., et al. (2010) Onset and Progression of Pathologic Atrophy in Huntington Disease: A Longitudinal MR Imaging Study. American Journal of Neuroradiology, 31, 1036-1041. [Google Scholar] [CrossRef] [PubMed]
[16] Pagano, G., Niccolini, F. and Politis, M. (2016) Current Status of PET Imaging in Huntington’s Disease. European Journal of Nuclear Medicine and Molecular Imaging, 43, 1171-1182. [Google Scholar] [CrossRef] [PubMed]
[17] Loane, D.J. and Kumar, A. (2016) Microglia in the TBI Brain: The Good, the Bad, and the Dysregulated. Experimental Neurology, 275, 316-327. [Google Scholar] [CrossRef] [PubMed]
[18] 卢仁睿, 张莉, 王慧慧, 等. 桃叶珊瑚苷对谷氨酸诱导的兴奋性神经毒性的抑制作用研究[J]. 中国现代应用药学, 2022, 39(24): 3197-3203.
[19] 庄泽锐, 刘明发, 骆健明, 等. 抑制星形胶质细胞丝裂原活化蛋白激酶14减轻谷氨酸兴奋性毒性神经元损伤的机制[J]. 中华创伤杂志, 2021, 37(9): 833-840.
[20] 李蓉, 刘露, 朱夕陈, 等. 洛伐他汀调节NMDA受体功能减缓NMDA兴奋性毒性损害[J]. 南京医科大学学报·自然科学版, 2023, 43(4): 468-474.
[21] Albin, R.L., Young, A.B. and Penney, J.B. (1989) The Functional Anatomy of Basal Ganglia Disorders. Trends in Neurosciences, 12, 366-375. [Google Scholar] [CrossRef] [PubMed]
[22] Plotkin, J.L. and Surmeier, D.J. (2015) Corticostriatal Synaptic Adaptations in Huntington’s Disease. Current Opinion in Neurobiology, 33, 53-62. [Google Scholar] [CrossRef] [PubMed]
[23] 张青, 周翠冰, 戴一凡, 等. 神经细胞异种移植的研究进展[J]. 器官移植, 2017, 8(4): 328-332.
[24] 张一平, 陈芸, 郑婷婷. 超声技术应用于帕金森病的研究进展[J]. 中国现代医生, 2023, 61(4): 104-107.
[25] 徐梦颖, 邱颐. 脑源性神经营养因子在神经退行性疾病中的作用[J]. 内蒙古医学杂志, 2021, 53(5): 550-554.
[26] 徐艳艳, 梅紫薇, 任雅君, 等. 超声技术应用于脑疾病治疗的研究进展[J]. 国际药学研究杂志, 2020, 47(1): 16-21.
[27] 王青松, 李雯, 雷文亮, 等. 中枢神经原位再生技术及其治疗前景[J]. 中国科学·生命科学, 2022, 52(10): 1426-1445.
[28] Tenore, G., Daglia, M., Ciampaglia, R. and Novellino, E. (2015) Exploring the Nutraceutical Potential of Polyphenols from Black, Green and White Tea Infusions—An Overview. Current Pharmaceutical Biotechnology, 16, 265-271. [Google Scholar] [CrossRef] [PubMed]
[29] 张静, 黄建安, 刘仲华. 茶叶功能成分抑制蛋白质聚集及错误折叠疾病的研究进展[J]. 食品科学, 2017, 38(13): 277-284.
[30] Lu, J.K., Hao, L.M., Tao, R.Y., et al. (2015) Antioxidant Activity of Green Tea Polyphenols and Theaflavins of Varied Purities. Journal of Food Science, 36, 17-21.
[31] 高广花, 王海学. 氘代药物Austedo (Deutetrabenazine)的研发案例分析[J]. 中国新药杂志, 2017, 26(18): 2159-2165.
[32] 王如意, 范晶菁, 李洪林, 等. 丁苯那嗪调节TH和突触囊泡转运改善HD的机制研究[J]. 华东理工大学学报(自然科学版), 2023, 49(2): 211-219.
[33] 杨君义, 张立菊. 治疗亨廷顿舞蹈症和迟发性运动障碍新药: Deutetrabenazine [J].中国新药与临床杂志, 2019, 38(3): 140-143.
[34] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. (2014) Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 38, 140-149. [Google Scholar] [CrossRef] [PubMed]
[35] 吴潦章, 杨瑾, 王净, 等. 二甲双胍调节AMPK/TGF-β1信号通路对百草枯中毒大鼠肺纤维化的保护作用[J]. 贵州医药, 2024, 48(1): 21-26.
[36] 李喆, 张振坤, 李亚, 等. 二甲双胍在神经退行性疾病预防和治疗中的研究进展[J]. 郑州大学学报·医学版, 2021, 56(2): 204-210.
[37] 沈冬杭, 李鑫, 郭世猛, 等. α-亚甲基-γ-丁内酯类GPR52拮抗剂的设计与合成研究[J]. 有机化学, 2023, 43(11): 3916-3929.
[38] 郑璐, 侯景轩, 郝帅帅, 等. GPR52——治疗神经系统疾病的新靶点[J]. 化学通报, 2022, 85(3): 303-308.
[39] 隋宁, 张子伟, 胡丹丹. 基于细胞内第二信使cAMP的检测评估化合物对多巴胺靶点的活性影响[J]. 临床研究, 2023, 31(6): 4-9.